Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | RXRA | P19793 | 2/20 | 0.46 |
| ▸ | RXRB | P28702 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | RXRG | P48443 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | PPARD | Q03181 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3621461 | 0.87 | NR1H4 (0.67) | HSD17B10NR1H4CYP2C19MEN1HTT | |
| SCHEMBL20576559 | 0.86 | HSD17B10 (0.62) | HSD17B10RXRARXRBRXRGPPARD | |
| SCHEMBL31306759 | 0.86 | HSD17B10 (0.62) | HSD17B10RXRARXRBRXRGPPARD | |
| SCHEMBL7854190 | 0.81 | KMT2A (0.47) | CYP2C19MEN1HTTKMT2ANPSR1 | |
| SCHEMBL18050385 | 0.80 | CYP2C19 (0.44) | HSD17B10NR1H4CYP2C19MEN1HTT | |
| SCHEMBL3207839 | 0.80 | MEN1 (0.46) | CYP2C19MEN1HTTKMT2AALDH1A1 | |
| SCHEMBL7795903 | 0.80 | CYP2D6 (0.59) | HSD17B10NR1H4CYP2C19MEN1KMT2A | |
| SCHEMBL11599008 | 0.78 | RXRA (0.56) | NR1H4CYP2C19RXRARXRBLMNA | |
| SCHEMBL6343545 | 0.78 | HSD17B10 (0.70) | HSD17B10MEN1HTTKMT2AGAA | |
| SCHEMBL13205866 | 0.78 | HSD17B10 (0.70) | HSD17B10GAANPSR1ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144743-A1 | COMPOUNDS | TMEM16A LIMITED (GB) | 2026-05-28 | — | — | US | disclosed |
| EP-4699655-A2 | COMPOUNDS | TMEM16A LIMITED (GB) | 2026-02-25 | — | — | EP | disclosed |
| US-12377105-B2 | Compounds | TMEM16A LIMITED (GB) | 2025-08-05 | — | — | US | disclosed |
| CN-119490451-A | Compounds as positive modulators of calcium activated chloride channels | TMEM16A有限公司 | 2025-02-21 | — | — | CN | disclosed |
| CN-111683926-B | Compounds of formula (I) | 企业治疗学有限公司 | 2024-11-08 | — | — | CN | disclosed |
| EP-4215520-A1 | TMEM16A MODULATORS | TMEM16A LIMITED (GB) | 2023-07-26 | — | — | EP | disclosed |
| EP-3743406-B9 | TMEM16A MODULATORS | TMEM16A LTD (GB) | 2023-03-08 | — | — | EP | disclosed |
| EP-3743406-B1 | TMEM16A MODULATORS | TMEM16A LTD (GB) | 2022-12-28 | — | — | EP | disclosed |
| US-20220395512-A1 | COMPOUNDS | TMEM16A LTD (GB) | 2022-12-15 | — | — | US | disclosed |
| US-11364246-B2 | Compounds | TMEM16A LIMITED (GB) | 2022-06-21 | — | — | US | disclosed |
| EP-1466906-A1 | Heterocyclic urea and related compounds useful as anti-inflammatory agents | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-10-13 | — | — | EP | disclosed |
| US-20040019038-A1 | Compounds useful as anti-inflammatory agents | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-01-29 | — | — | US | disclosed |
| US-6660732-B2 | Compounds useful as anti-inflammatory agents | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-12-09 | — | — | US | disclosed |
| US-20030225077-A1 | Intermediate arylamine compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-12-04 | — | — | US | disclosed |
| US-6656933-B2 | Novel compounds which inhibit production of cytokines involved in inflammatory processes | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-12-02 | — | — | US | disclosed |
| US-20020082256-A1 | Compounds useful as anti-inflammatory agents | BETAGERI RAJASHEHAR (US) | 2002-06-27 | — | — | US | disclosed |
| US-20020055507-A1 | Compounds useful as anti-inflammatory agents | BETAGERI RAJASHEHAR (US) | 2002-05-09 | — | — | US | disclosed |
| US-6358945-B1 | CYTOKINE, TUMOR NECROSIS FACTOR, AND INTERLEUKIN INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-03-19 | — | — | US | disclosed |
| EP-1165516-A2 | HETEROCYCLIC UREA AND RELATED COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000055139-A2 | HETEROCYCLIC UREA AND RELATED COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2000-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144743-A1 | COMPOUNDS | CACNA1E, TMEM109, CACNA1C | HSD17B10 868/4885NR1H4 1840/4885CYP2C19 2243/4885 |
| US-11364246-B2 | Compounds | CACNA1E, TMEM109, CACNA1A | HSD17B10 2679/4885NR1H4 2677/4885CYP2C19 2982/4885 |
| US-20030225077-A1 | Intermediate arylamine compounds | AHR, AADAC, NAT1 | HSD17B10 967/4885NR1H4 138/4885CYP2C19 123/4885 |
| US-20220395512-A1 | COMPOUNDS | CACNA1E, TMEM109, CACNA1A | HSD17B10 2273/4885NR1H4 2976/4885CYP2C19 2789/4885 |
| US-20020082256-A1 | Compounds useful as anti-inflammatory agents | NFKBIA, TNF, MPO | HSD17B10 1561/4885NR1H4 214/4885CYP2C19 1588/4885 |
| US-20020055507-A1 | Compounds useful as anti-inflammatory agents | NFKBIA, TNF, MPO | HSD17B10 1561/4885NR1H4 214/4885CYP2C19 1588/4885 |
| US-20040019038-A1 | Compounds useful as anti-inflammatory agents | NFKBIA, TNF, MPO | HSD17B10 1561/4885NR1H4 214/4885CYP2C19 1588/4885 |
| US-12377105-B2 | Compounds | CACNA1E, TMEM109, CACNA1A | HSD17B10 2273/4885NR1H4 2976/4885CYP2C19 2789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.